TG Therapeutics, Inc. (TGTX) Stock Forecasts

TG Therapeutics (TGTX) presented Phase 1 data for azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive multiple sclerosis. 89% of evaluable participants showed stable or improved disability scores at Day 90, with no high-grade toxicities observed. The study included 26 participants, with a median follow-up of 4.9 months.

TG Therapeutics (TGTX) reported Phase 1 trial results for azercabtagene zapreleucel in progressive MS patients. 89% of participants showed stable or improved EDSS scores at Day 90, with no high-grade toxicities observed. The study is ongoing with limited participants and short follow-up.

TG Therapeutics (TGTX) shared initial Phase 1 data for azer-cel in 26 progressive MS patients, showing B-cell depletion and stable or improved disability in 18 evaluable patients, with five showing EDSS improvements. Follow-up is short, and dose escalation continues.

TG Therapeutics reported initial results from a Phase 1 study of azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive MS patients. No severe side effects were observed, and 89% of evaluable patients had stable or improved disability scores. Michael S. Weiss, CEO, highlighted the potential of this off-the-shelf therapy for progressive MS. The study included 26 participants with a median follow-up of 4.9 months.

TG Therapeutics (TGTX) presented long-term data on its MS drug BRIUMVI at a medical conference, showing 88% of patients had no disability progression after seven years. The company also shared updates on Phase 1 and 3 trials, including potential quarterly dosing. TGTX has a market cap of $8.35B, P/E of 19.86x, and a GF Score of 61/100. Insiders have been selling shares, while some institutional investors have increased stakes.

TG Therapeutics (TGTX) announced seven-year data for BRIUMVI, Phase 3 dosing results, and Phase 1 subcutaneous data. The company also shared real-world updates and initial Phase 1 results for azer-cel in PPMS. These updates may support BRIUMVI's lifecycle and early pipeline options in MS, but larger catalysts will require further peer-reviewed results or regulatory filings.